Method for using gene expression to determine prognosis of prostate cancer

US10260104B2 · kind B2 · utility

Assignee

• Genomic Health, Inc. · US

Inventors

• Steven Shak · Burlingame, US
• Frederick L. Baehner · San Francisco, US
• Tara Maddala · Sunnyvale, US
• Mark Lee · Burbank, US
• Robert J. Pelham · Belmont, US
• Wayne Cowens · Tiburon, US
• Diana Cherbavaz · San Francisco, US
• Michael C. Kiefer · Clayton, US
• Michael Crager · Menlo Park, US
• Audrey Goddard · San Francisco, US
• Joffre B. Baker · Montara, US

Key dates

• Filing date: Oct 20, 2015
• Grant date: Apr 16, 2019
• Expiry date: May 12, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q2600/178
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The present disclosure includes assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for the patient, and likelihood that the patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status.